Durect (DRRX)

[turning stone]

Will the person or group that purchased 141,000 shares right at the end of the day please stand up.

[ClayTrader]

* * $DRRX Video Chart 07-31-2019 * *

Link to Video - click here to watch the technical chart video

[MoneyUnder]

Earnings will result in positive news. Warrants at $1.43, no dilution or increase in shares the last 4-5 10-Qs, partnership w gilead, needs to stay above $1. Nice daily chart. In at 1.04 to the upside

[turning stone]

I understand where you are coming from but I disagree on a buy out. They have plenty of cash to cover their Phase 1-2-3 of their pipeline so I think they will go it alone. What we don't know is the thoughts of major management to want one big bundle of money and then cut and run or think of those who put them in the position to even think about cut and run WE THE SHAREHOLDERS.

[BooDog]

Buy out potential imo. See how this looks in the Fall.

[BooDog]

Short Float 2.21% Shs Float 177.30M Inst Own 38.20%

https://finviz.com/quote.ashx?t=DRRX

DURECT and Gilead Enter into License Agreement for Long-Acting Injectable HIV Investigational Product

https://finance.yahoo.com/news/durect-gilead-enter-license-agreement-120000560.html

Give it up shorty. Float isn't terribly small enough to let you close the gap.

But if you do...…...........

[ClayTrader]

* * $DRRX Video Chart 07-23-2019 * *

Link to Video - click here to watch the technical chart video

[hmuney]

@turning stone: No worries and I'm also invested in $DRRX for over a year now. Probably not as heavily as others, but nevertheless invested. I'm very blunt with posting, so I can see how I get misunderstood.

I don't have a medical background, but believe in companies that are trying to improve lives. I appreciate anyone who posts facts from official sources and documentation, such as clinicaltrials.gov. I obviously prefer good news, but anything to stay informed helps. If you have any information in the future, please do share.

[ClayTrader]

* * $DRRX Video Chart 07-22-2019 * *

Link to Video - click here to watch the technical chart video

[turning stone]

*hmuney* I am sorry if I miss-understood what you were trying to say. You sounded like a shorter and I am very anti these kind of people. I have a very heavy investment in this company. I do realize that people come on these boards and just say anything just to blow off their mouth. I also understand the real investors don't realize this board is here. Again I apologize for taking your post the wrong way.
I come from a very heavy medical background and try to protect this field from pure jerks that are out there.

[Welsh_Dragon]

Shorts are losing. They will give up and let this rise in due course.

[BooDog]

I didn't think they'd be able to fill the gap. It could take MONTHs if not years to fill that gap.

Averaged right about .8 for me after averaging up.

Certainly claytrader and crew are trying to work this.

[Welsh_Dragon]

Nice adds in 80s and low 90s on that short attack. Pushing back to $1 now.

[BooDog]

Okay, I'm good. Stink bid in just incase they try and close the gap a bit.

GLTA!!!

[Welsh_Dragon]

Light volume in pre market considering the potential. More deals to come, looks like a long term hold here.

[BooDog]

Thinking it won't be for long after it opens. Just got into this one last week lol. Added a little already and may again here soon.

Yes, excellent news. Need a couple of my other bios to get a similar deal!!

Congrats!!!

[Welsh_Dragon]

Sparkling news and still available under $1

[BooDog]

DURECT and Gilead Enter into License Agreement for Long-Acting Injectable HIV Investigational Product

https://finance.yahoo.com/news/durect-gilead-enter-license-agreement-120000560.html

Under the terms of the agreement, Gilead will make an upfront payment to DURECT of $25 million, with the potential for up to an additional $75 million in development and regulatory milestones, up to an additional $70 million in sales based milestones, as well as tiered royalties on product sales. Gilead has the exclusive option to license additional SABER-based products directed to HIV and HBV for an additional $150 million per product in upfront, development, regulatory and sales based milestones as well as tiered royalties on sales. The parties will collaborate on specified development activities with Gilead controlling and funding the development programs.

[hmuney]

I think there's a misunderstanding. I was unaware until someone else pointed out (elsewhere) that this was already expected and Durect just needed to update their ClinicalTrials documents. I'm bullish and was simply posting facts. I'm being objective, scaring wasn't the intention.

I sent this privately to @turning stone, but figured I should clarify to anyone else who got offended.

[turning stone]

Hmuney

So what's your point? If you are trying to scare investors you are showing how mindless you are. This board has no interest to the true real investors in this company. I suggest you crawl back under the rock you came back out from.

[hmuney]

Sounds like this trial/program was shut down in January and mentioned in a PR, so not new info.

[hmuney]

One of the $DRRX clinical studies was terminated. Study update was posted today 7/18:

"A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)"

https://clinicaltrials.gov/ct2/show/record/NCT03394781

[BooDog]

Should get some interest imo, may have the green light late December.

[rebex9]

LATEST NEWS!!! DURECT Announces that the FDA Agreed to File the Full Response to the POSIMIR® Complete Response Letter as a Complete Class 2 Resubmission

IT'S ON OTC NEWS

[rebex9]

LATEST NEWS!!! DURECT Announces that the FDA Agreed to File the Full Response to the POSIMIR® Complete Response Letter as a Complete Class 2 Resubmission

https://www.otcmarkets.com/stock/DRRX/news/story?e&id=1396378

[rebex9]

LATEST NEWS!!! DURECT Announces that the FDA Agreed to File the Full Response to the POSIMIR® Complete Response Letter as a Complete Class 2 Resubmission

https://www.otcmarkets.com/stock/DRRX/news/story?e&id=1396378

[hmuney]

DUR-928 AH study update on clinicaltrials.gov. "Estimated Primary Completion Date: September 2019 (Final data collection date for primary outcome measure)"

https://clinicaltrials.gov/ct2/show/record/NCT03432260

[turning stone]

If DRRX can stay the course until the really great news breaks I will be very happy. Bio-pharma actions moves very slowly until the big news breaks out of the bottle.

[turning stone]

I would very much doubt a reverse split as they are usually a kiss of death. With a 6 month extension that runs into the FDA possible approval. If they do so DURECT would be foolish to go through with a reverse split.


THIS IS STRICTLY JUST MY OPINION

[Bunti]

Today's options Volume for $2.5 call expires on Jan 17, 2020 is 134.

[Bunti]

I planning for long term too buddy.

[harry crumb]

Got in. Why not. Could hit $5 on a pop an run! $$$

[whytestocks]

News: $DRRX DURECT Announces Completion of the 90 mg Severe Cohort and Dose Escalation Committee Approval to Commence 150 mg Dosing in Patients with Severe Alcoholic Hepatitis (AH) in its Ongoing DUR-928 Phase 2a AH Trial

CUPERTINO, Calif. , June 18, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has completed dosing the 90 mg cohort of severe AH patients in its ongoing DUR-928 Phase 2a clinical trial, and that after reviewing safety and pharmacokinetic (PK) data from the co...

Read the whole news https://marketwirenews.com/news-releases/durect-announces-completion-of-the-90-mg-severe-cohort-and-dose-escalation-committee-approval-to-commence-150-mg-dosing-in-patients-with-severe-alcoholic-hepatitis-ah-in-its-ongoing-dur-928-phase-2a-ah-trial-8373906.html

[Youlie]

What reverse split?

They have until 6/24. Then a 180 day extension.

[whytestocks]

News: $DRRX DURECT to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019

CUPERTINO, Calif. , May 16, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown , Chief Executive Officer, and Michael H. Arenberg , Chief Financial Officer, will be participating in the 20 th Annual B. Riley FBR Institutional Investor Confer...

Read the whole news https://marketwirenews.com/news-releases/durect-to-present-at-the-20th-annual-b-riley-fbr-institutional-investor-conference-on-may-22-2019-8202078.html

[DialedIn2Trade]

HUGE buys happening right now...somebody is betting on the Phase II results to be great!!!!

[ClayTrader]

* * $DRRX Video Chart 05-06-2019 * *

Link to Video - click here to watch the technical chart video

[Jeffryac]

WE ROLLIN!!! THEY HATTIN!!!

[Jeffryac]

AWWW poor clay... not a good day today for u I see

[ClayTrader]

* * $DRRX Video Chart 05-03-2019 * *

Link to Video - click here to watch the technical chart video

[Jeffryac]

BIG MOVE TODAY !!!!

[whytestocks]

News: $DRRX DURECT Corporation to Present Preliminary Data from the Ongoing DUR-928 Alcoholic Hepatitis Phase 2a Trial and Report First Quarter 2019 Financial Results

CUPERTINO, Calif. , May 3, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report preliminary data from the ongoing DUR-928 alcoholic hepatitis (AH) trial and its financial results for the three months ended March 31, 2019 after the market close on T...

Got this from https://marketwirenews.com/news-releases/durect-corporation-to-present-preliminary-data-from-the-ongoing-dur-928-alcoholic-hepatitis-phase-2a-trial-and-report-first-quarter-2019-financial-results-8110964.html

[Youlie]

Getting ready to move up

[THREE-DAY-TRADER]

Glad I Stopped Out of this $DRRX turkey the other day before it fell to new lows today. Took the small % loss. Sometimes it happens as a reality necessary of trading.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144274929

The last 2 trades of stocks for private e-mail followers were very profitable however (all cannabis stocks).
$VVC*F sold for 25-38% profit range last week.
$PO*N sold 10/16 for a solid 50% profit.

[THREE-DAY-TRADER]

Nice move today (10/30) to close up @ 1.07. Let's see if it has further follow thru.

Seems to finally be 'basing' in the short term from the .92 support low first established about 3 weeks ago in October.
Avg cost near 1.00 on $DRRX.
Let's see what happens yet going forward.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144274929

[THREE-DAY-TRADER]

Seems to finally be 'basing' in the short term since about 2 weeks ago from the .92 support low.
Avg cost near 1.00 on $DRRX.
Let's see what happens yet going forward.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144274929

[THREE-DAY-TRADER]

Let's see if .92+ holds as support yet in the short term. Avg cost near 1.00 on $DRRX

[THREE-DAY-TRADER]

Looking for a new support level yet on $DRRX. The prior couple weeks of basing from 1.02 did not pan out.
A broad market sell off along with pharma - biotech sector this week also has not helped any

[THREE-DAY-TRADER]

$DRRX ~ Seems to basing since 9/24 with good support again this week (as a double bottom) from the 1.02 low which I earlier pointed out since 9/25.
Still nice entry levels as of today (10/3) at about 1.10 Limit or less in my opinion.

9/25/18:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143793122

[THREE-DAY-TRADER]

$DRRX up today thru 9/26 so far since I pointed it out yesterday
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143793122